Outlook Therapeutics, Inc. OTLK
0.64
(0.02)
(3.03%)
as of 25 Sep
- Market cap
- $159.5M
- P/E
- 0.0×
Follow OTLK
Insider Buys
alert about insiders buying in the last 12 month
| Sep '25 | Sep '24 | Sep '23 | Sep '22 | Sep '21 | Sep '20 | Sep '19 | Sep '18 | Sep '17 | Sep '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.70 | — | — | — | — | — | 3.33 | 12.52 | 8.76 | 24.56 |
P/FCF ratio |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(2.98) | — | — | — | — | — | (4.56) | (4.61) | 418.32 | (7.06) |
P/B ratio |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
10.09 | — | — | — | — | — | 3.71 | 17.41 | 11.46 | 24.82 |
EV/EBITDA |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.53) | — | — | — | — | — | (0.94) | (1.63) | (2.82) | (1.63) |
EV/FCF |
(1.51) | — | — | — | — | — | (0.92) | (1.50) | (2.76) | (1.59) |
Quick Ratio |
0.21 | 0.35 | 0.50 | 0.88 | 2.14 | 0.79 | 0.40 | 0.05 | 0.11 | 0.12 |
Current Ratio |
0.38 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 | 0.67 | 0.10 | 0.14 | 0.28 |
Net Debt/EBITDA |
(0.33) | (0.20) | (0.23) | 0.10 | 0.05 | 0.32 | (0.09) | (0.57) | (0.31) | (0.02) |
Debt/Assets |
161.14% | 102.14% | 110.06% | 38.28% | 51.76% | 5.05% | 65.02% | 75.38% | 64.93% | 12.36% |
Debt/Equity |
(0.93) | (0.40) | (2.46) | 1.25 | 2.56 | 0.35 | (1.03) | (0.81) | (0.44) | (0.61) |
Asset Turnover |
0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.41 | 0.14 | 0.17 | 0.10 |
Operating CF/Net income |
0.83 | 0.91 | 0.73 | 0.86 | 1.02 | 0.65 | 0.90 | 0.69 | 0.39 | 0.72 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.13) | (0.91) | (0.11) | (0.46) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 118.61% | 172.24% | 2,069.13% | (989.99%) | (1,430.32%) | 734.77% | 172.96% | 162.24% | 206.19% | 210.30% | |
| (263.36%) | (246.60%) | (193.93%) | (257.32%) | (249.92%) | (265.13%) | (182.86%) | (223.25%) | (173.50%) | (209.02%) | |
ROIC |
0.00% | 0.00% | 0.00% | (1,744.91%) | (1,669.72%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
219.61% | 497.87% | 375.05% | (840.24%) | (356.33%) | (2,051.54%) | 997.61% | 468.50% | 457.74% | (1,618.87%) |
Average Days of Receivables |
384.99 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
1,922.93% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 292.23% | 599.30% | 624.68% | 1,099.58% |
Selling, General and Administrative Expense of Revenue |
2,825.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 115.02% | 460.80% | 416.69% | 723.71% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
629.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.12% | 64.32% | 224.88% | 417.84% |
Graham Net Nets |
(0.91) | — | — | — | — | — | (0.53) | (1.03) | (1.42) | (0.34) |
Graham Number |
6.11 | — | — | — | — | — | 140.11 | 735.03 | 1,142.26 | 787.12 |
Earnings Yield |
(169.27%) | — | — | — | — | — | (165.10%) | (147.83%) | (116.31%) | (84.23%) |
Free Cash Flow Yield |
(141.71%) | — | — | — | — | — | (120.74%) | (92.64%) | (47.32%) | (63.66%) |
Revenue per Share |
0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.96 | 12.52 | 25.39 | 27.69 |
Operating CF per Share |
(1.49) | (3.71) | (3.44) | (5.34) | (7.11) | (8.76) | (35.50) | (133.98) | (103.30) | (422.70) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.48) | (11.28) | (1.95) | (10.21) |
Free Cash Flow per Share |
(1.49) | (3.71) | (3.44) | (5.34) | (7.11) | (8.76) | (35.98) | (145.26) | (105.24) | (432.91) |
Cash per Share |
0.23 | 0.80 | 1.87 | 1.64 | 1.90 | 3.46 | 8.81 | 6.96 | 21.22 | 21.86 |
Shareholders Equity per Share |
(0.92) | (3.94) | (1.15) | 0.82 | 0.60 | 0.78 | (11.84) | (84.39) | (204.71) | (48.08) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.92) | (3.94) | (1.15) | 0.82 | 0.60 | 0.78 | (11.84) | (84.39) | (204.71) | (48.08) |
Free Cash Flow |
(51.83) | (68.79) | (42.97) | (56.67) | (54.25) | (31.79) | (32.73) | (35.82) | (15.80) | (46.58) |
Working Capital |
(28.43) | (15.14) | (15.75) | 7.79 | 14.76 | 2.06 | (6.79) | (28.74) | (24.83) | (14.76) |
Capital Expenditures |
— | — | — | — | — | — | (0.44) | (2.78) | (0.29) | (1.10) |
Net Current Asset Value |
(33.38) | (74.48) | (15.76) | 7.73 | 3.30 | 1.04 | (14.40) | (39.79) | (47.56) | (24.90) |
EV/EBIT |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | — | — | — | — | — | 0.05 | 0.90 | 0.08 | 0.37 |
Net Profit Margin |
(4,416.34%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (442.42%) | (1,555.22%) | (1,050.14%) | (2,119.04%) |
Price to Operating Income |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 1.69 | 2.91 | 1.60 | 1.69 | 1.06 | 0.17 | 0.17 | 0.13 |
Cash ROIC |
(887.13%) | 239.62% | (96.62%) | (153.15%) | (176.16%) | (196.32%) | (422.88%) | 2,244.81% | 224.43% | (20,044.16%) |
Accounts Receivable Turnover |
0.49 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.15 | 0.00 | 0.01 | 0.07 | 0.11 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
2,742.92 | 0.00 | 54,291.69 | 6,225.68 | 3,058.56 | 1,577.52 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
898.41 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Receivables |
2.90 | — | — | — | — | — | — | — | — | — |
Average Payables |
9.08 | 7.27 | 5.03 | 2.84 | 2.30 | 2.34 | 2.94 | 7.28 | 8.01 | 8.32 |
Average Assets |
23.70 | 30.56 | 30.41 | 25.67 | 21.27 | 18.43 | 19.71 | 21.51 | 23.07 | 30.21 |
Average Common Equity |
(52.63) | (43.76) | (2.85) | 6.67 | 3.72 | (6.65) | (20.84) | (29.60) | (19.41) | (30.02) |
Columns are period end dates